Mielóma multiplex: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• BCMA 134
• CD38 22
• GPRC5D 36
• CD19 31
• TP53 0
• STAT3 0
• CXCR4 3
• MYC 0
• BCL-2 2
• PI3K 1
• mTOR 0
• IL-6 0
• STING 0
• BRAF 2
• CD47 1
• HDAC 0
• AKT 0
• PD-1 1
• PD-L1 1
• CD20 3
• GLP-1 0
• JAK 0
• PTEN 0
• SGLT2 0
• TIGIT 0
• AMPK 0
• B7-H3 0
• NRAS 1
• CTLA-4 1
• ERK 0
• EZH2 0
• FTO 0
• IL-15 3
• JNK 0
• KRAS 1
• MAPK 0
• RAS 0
• CD22 2
• CD33 1
• CTNNB1 0
• EGFR 0
• FGFR 0
• LAG-3 0
• MDM2 0
• METTL3 0
• NRF2 0
• BRCA1 0
• BRD4 0
• BTK 1
• CD123 1
• CD30 0
• CDK4/6 0
• GPX4 0
• HER2 0
• HIF-1 0
• HSP90 0
• MEK 0
• MET 0
• MUC1 0
• NTRK 0

1872 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIAMS · R01

  Modulation of Bone Formation and Fracture Repair During Cancer Development

  Washington University· Saint Louis, Egyesült Államok· 577 398 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R50

  Curing Through Cooperation: Aligning Cooperative Groups to Investigate Novel Therapeutic Approaches to Cure Plasma Cell Dyscrasias

  Utah State Higher Education System--University of Utah· Salt Lake City, Egyesült Államok· 173 767 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R44

  Detection and Isolation of Circulating Myeloma Cells: Toward a Minimally-Invasive CLIA-Certified Diagnostic for Multiple Myeloma

  Cellsbin, Inc.· Branford, Egyesült Államok· 1 045 925 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · U01

  Comparative Modeling of Multiple Myeloma Prevention, Early Detection and Treatment Interventions

  Washington University· Saint Louis, Egyesült Államok· 848 978 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Overcoming CAR T cell resistance by tumor-restricted IL-12 driven anti-tumor immunity

  University of California Los Angeles· Los Angeles, Egyesült Államok· 477 666 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Svédország· EU contribution 2 000 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Microbiome-Driven Modulation of Immune Reconstitution and Vaccine Responsiveness in Multiple Myeloma Patients following Stem Cell Transplantation (MicroMM)

  Technische Universitaet Muenchen· Muenchen, Németország· EU contribution 1 466 571 EUR· until 2031. okt.

• European Commission (Horizon Europe) · HORIZON-RIA

  iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY (iN-KEY)

  Banc de Sang I Teixits· Barcelona, Spanyolország· EU contribution 9 998 178 EUR· until 2031. szept.· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A CEllulaR immunoTherapy virtuAl twin for personalIsed cancer treatmeNT (CERTAINTY)

  Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev· Munchen, Németország· EU contribution 9 999 253 EUR· until 2028. máj.· 8 countries

10 of 332 running projects, newest first. Listed amounts together: 252,1 M USD + 35,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Felfüggesztve

  Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

  NCT06876142· National Cancer Institute (NCI)· Frissítve: 2026. nov. 13.

  “Administrative hold pending non-safety related changes to the study design.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma

  NCT05996367· Instituto do Cancer do Estado de São Paulo· Frissítve: 2026. nov. 4.

  “Funding/ transfer PI”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

  NCT04268199· AHS Cancer Control Alberta· Frissítve: 2026. okt. 28.

  “Operational limitations”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

  NCT06179888· National Cancer Institute (NCI)· Frissítve: 2026. okt. 19.

  “Scheduled Interim Monitoring”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  64Cu-LLP2A for Imaging Hematologic Malignancies

  NCT06636175· Washington University School of Medicine· Frissítve: 2026. okt. 16.

  “Loss of further funding”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  The Feasibility and Effects of Exercise on Patients Suffering From Multiple Myeloma

  NCT04300335· Medical University of Vienna· Frissítve: 2026. okt. 9.

  “The study was not started because the necessary resources could not yet be secured after COVID-19, which was the reason for the initial interruption of the study.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease

  NCT06572605· City of Hope Medical Center· Frissítve: 2026. okt. 7.

  “pending amendment”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

  NCT06232044· Alliance for Clinical Trials in Oncology· Frissítve: 2026. okt. 2.

  “Enrollment to Dose Level 1 cohort has been met”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

  NCT04401020· Sanofi· Frissítve: 2026. szept. 29.

  “Sponsor decision based on limited clinical benefit observed in both Multiple Myeloma and Non-Hodgkin Lymphoma cohorts”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma

  NCT05874193· Cristiana Costa Chase, DO· Frissítve: 2026. szept. 28.

  “Due to barriers in anticipated accrual”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

  NCT06400251· National Cancer Institute (NCI)· Forrás

• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

  NCT06876142· National Cancer Institute (NCI)· Forrás

• In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

  NCT05093335· Memorial Sloan Kettering Cancer Center· Forrás

• A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide

  NCT04497961· Memorial Sloan Kettering Cancer Center· Forrás

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Forrás

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Pfizer· Forrás

• 18F-Fluciclovine PET/CT in Multiple Myeloma

  NCT06103838· National Cancer Institute (NCI)· Forrás

• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

  NCT02682667· National Cancer Institute (NCI)· Forrás

• Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Hoffmann-La Roche· Forrás

• Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

  NCT04091126· GlaxoSmithKline· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 23
• Organoids 3
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 8
• Gene Expression Profiling 44
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Exome Sequencing 3
• Proteomics 15
• Metabolomics 10
• Mass Spectrometry 7
• Flow Cytometry 48
• Immunohistochemistry 11
• Liquid Biopsy 2
• Circulating Tumor DNA 2
• Xenograft Model Antitumor Assays 78
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 26
• Machine Learning 17
• Deep Learning 6
• Cohort Studies 32
• Genome-Wide Association Study 7

• Light Chain Crystalline Proximal Tubulopathy and Podocytopathy With Staining for Both Light and Heavy Chain Immunoglobulin.

  Nephrology (Carlton), 2026. aug.

• Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.

  Am J Clin Pathol, 2026. júl.

• [Diagnostic value of minimal endometrial sampling combined with CD138+MUM-1 dual immunostaining for chronic endometritis in FET cycles: a propensity score matching retrospective cohort study].

  Zhonghua Fu Chan Ke Za Zhi, 2026. jún.

• Multifocal non-epitheliotrophic cutaneous B-cell Lymphoma in a dog: cytologic, histopathologic, immunophenotypic, and molecular findings.

  BMC Vet Res, 2026. jún.

• Validation of a QuPath-Based Artificial Intelligence Workflow for Plasma Cell Quantification on CD138 Immunohistochemistry in an Indian Hematopathology Cohort.

  Clin Lymphoma Myeloma Leuk, 2026. jún.

• Multiple Myeloma Concomitant with AL Amyloidosis: Histopathological Aspects of the Common Plasma Cell Spectrum.

  Int J Mol Sci, 2026. jún.

• CEACAM1 expression by immunohistochemistry in B-cell lymphomas and plasma cell myeloma.

  Am J Clin Pathol, 2026. jún.

• The diagnostic utility and frequency of CD56 expression in plasma cell myeloma.

  Ann Diagn Pathol, 2025. nov.

• The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma.

  Medicina (Kaunas), 2025. okt.

• Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases.

  Oncotarget, 2017. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.